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South Africa (SA), located at the southern tip of 
Africa, is divided into nine provinces (Fig. 1). 
The Western Cape and Gauteng provinces are the 
most densely populated regions and, together with 
KwaZulu-Natal Province, contribute two-thirds of 
the economy of the country.[1]
Of the total SA population of 52 million, 49% are males. About 79% 
are black African, 9% white, 2.5% Asian or Indian and 9% coloured. 
The population is young: 73% are aged under 40 years, 30% under 15 
and 11% under 5. The birth rate is 19/1 000, with an infant mortality 
rate of 42/1 000 live births; the under-5 mortality rate is 60/1 000 live 
births. The most common causes of death in children under 5 years 
of age are diseases of infectious origin and malnutrition.[1]
Over 80% of South Africans have no health insurance, and 15% 
pay for private insurance.[2] In public hospitals treatment is free for 
all children below the age of 6 years, while modest income-based 
contributions are required for older children. A new National 
Health Insurance scheme to provide basic health cover for all will 
be implemented shortly, according to the policy Green Paper of 
the National Department of Health published in 2011. The Health 
System Trust assessed in 2012 that there are 3  880 primary public 
healthcare facilities. These may refer patients with a diagnosis 
of cancer to a secondary hospital. If the diagnosis is confirmed, 
paediatric patients are referred to the relevant paediatric oncology 
unit (POU) for treatment.
Africa has 1 billion inhabitants, of whom 41% are younger than 
15 years of age.[3] Over 36  000 children are diagnosed with cancer 
annually, and their number is increasing with improving control of 
infectious diseases. In any given year, the ratio of children who die 
from cancer represents 60% of those diagnosed; the equivalent figure 
is 20% or less in developed countries of Europe and North America.[4] 
Data on which the above figures are based are extremely scarce. Only 
about 2% of the total population of Africa is covered by population-
based cancer registries producing comparable incidence figures.[5]
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Background. Childhood cancer is an emerging problem in Africa. Its extent is hazy because data are scarce, but it should be addressed. This 
is the first report from the South African Children’s Tumour Registry (SACTR), which covers the whole of South Africa (SA). It provides 
minimal estimates of cancer incidence and discusses the challenges of cancer surveillance and control in a child population in a middle-
income country. Only about 2% of the African population is covered by cancer registries producing comparable incidence data.
Objective. To present and interpret incidence patterns and trends of childhood cancer over a 21-year period. The results should raise 
awareness of the problem of childhood cancer in an African population and provide sensible data for taking this problem in hand.
Methods. All eligible and validated cancer cases registered in the SACTR over the period 1987 - 2007 and classified according to the 
International Classification of Childhood Cancer were included. Population data were retrieved from official sources and estimated for the 
population subcategories. Incidence rates were standardised to the world standard and time trends were evaluated using joinpoint models, 
adjusting for sex and age.
Results. Based on the 11 699 cases, the overall age-standardised average annual incidence rate was 45 per million. Threefold differences in 
the overall incidence rates were observed between the ethnic groups, ranging from 116 for whites to 37 for black Africans, and they differed 
by diagnostic group. Differences between the nine provinces of SA relate to the ethnic composition and prevailing socioeconomic status. 
The overall incidence rate declined by 1.2% per year for the whole country (p<0.01). However, the decline was mainly observed during the 
first few years of the study period, after which rates stabilised or increased.
Conclusions. Diagnosis and notification of childhood cancer should improve. The differences in incidence between ethnic groups suggest 
the priorities for cancer control.
S Afr Med J 2015;105(11):939-947. DOI:10.7196/SAMJ.2015.v105i11.9780
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Collection of data on childhood cancers 
throughout the country was started in 1987 
by the South African Children’s Cancer 
Study Group (SACCSG) as a collaboration 
between the nine referral POUs shown in 
Fig. 1.
The objective of the South African Child-
ren’s Tumour Registry (SACTR) is to describe 
the cancer burden in the national childhood 
population. In this first report from the 
SACTR, we aimed to present and interpret 
incidence patterns and trends of childhood 
cancer over a 21-year period (1987 - 2007) 
in this ethnically diverse population. The 
results should raise awareness of the problem 
of childhood cancer in an African population 
and provide sensible data for dealing with 
this problem.
Methods
The South African Children’s 
Tumour Registry
During 1987 - 2007, the nine POUs (Fig. 1) 
treated children with cancer and provid-
ed data to the SACTR. More recently, the 
SACTR data sources have included two new 
satellite units in the Eastern Cape Province 
and one in KwaZulu-Natal. Each POU sends 
its data to the central SACTR office as elec-
tronic files or as physical records by registered 
post. In addition to the POU sites, data also 
come from several oncologists treating chil-
dren with cancer in private healthcare institu-
tions and from some private paediatricians.
In the central registry, the relevant 
information is recorded into the electronic 
database of a customised CanReg 4 computer 
program, adapted for childhood cancer 
by the International Agency for Research 
on Cancer (IARC). Data are validated in 
collaboration with the data originators. 
Duplicate registration is prevented by 
manual matching of new cases. Relapses 
are matched with earlier registration of 
the same patient and flagged. Since 2002, 
information on tumour site, morphology 
and behaviour has been coded according to 
the International Classification of Diseases 
for Oncology, 3rd edition (ICD-O-3).[6] The 
cases originally coded to the ICD-O-2[7] were 
recoded to the ICD-O-3 in agreement with 
the original medical records. The registry 
respects confidentiality principles at all 
times. Identifying information is used for 
data input, quality control and follow-up. In 
all reports only grouped data are presented.
Cancer cases
The SACTR records all malignant tumours, 
as well as non-malignant central nervous 
system (CNS) tumours, occurring in chil-
dren aged under 15 years of age who are 
resident in SA. Children are considered 
resident if their parents have been resident 
for >12 months or if they themselves have 
lived in SA for at least 6 months, according 
to the identity documents examined by 
designated administrative personnel.
Records of all patients registered during 
the period 1987 - 2007 included identi-
fication number, province of residence, 
gender, age in years, ethnic group, dates of 
birth and diagnosis, tumour site, histological 
classification, behaviour and most valid 
basis of diagnosis. The extracted data were 
verified in collaboration with the IARC and 
converted to the International Classification 
of Childhood Cancer, 3rd edition (ICCC-3).[8]
Population data
Population data were obtained from the 
United Nations[9] and from Statistics South 
Africa,[1] although these sources did not 
provide figures for all cross-categories of 
gender, age, ethnic group and province 
in each calendar year. We were able to 
extract 1 201 data cells within the study 
period and a further 122 from the 
preceding or succeeding years. We have 
estimated the missing population figures 
by linear interpolation or extrapolation of 
available data, using the relevant gender, 
age, ethnic and province categories. The 
derived population estimates are based on 
the assumptions of linear population growth 
within the population subcategories over the 
periods with unavailable data. The estimated 
population data used for calculating the 
incidence rates in this study are shown in 
Table 1.
Analysis of incidence rates
Incidence rates are expressed as an average 
annual number of cases per million person-
years.[10] The age-standardised average 
annual incidence rate (ASR) for the age 
range 0 - 14 years is the weighted average 
of the age-specific incidence rates using the 
weights of the world standard population for 
the age groups 0 - 4, 5 - 9 and 10 - 14 years. 
Fig. 1. Map of SA showing the nine provinces and the location of the nine POUs. (Adapted from Htonl/
CC-BY-SA-3.0 of 25 January 2010, available from http://commons.wikimedia.org/wiki/File:Map_of_
South_Africa_with_English_labels.svg. 1 = Tygerberg Hospital (referral for the Western Cape); 2 = 
Red Cross War Memorial Children’s Hospital (referral for the Western Cape and Eastern Cape); 3 = 
Universitas/Pelonomi Academic Hospital Complex (referral for the Free State, Northern Cape and 
parts of the Eastern Cape and North West); 4 = Kalafong Hospital (referral for Northern Gauteng 
and Mpumalanga); 5 = H F Verwoerd Hospital (referral for Northern Gauteng and Mpumalanga); 
6 = Ga-Rankuwa/George Mukhari hospitals (referral for Limpopo); 7 = Chris Hani Baragwanath 
Hospital (referral for southern Gauteng and North West); 8 = Charlotte Maxeke Hospital (referral for 
southern Gauteng and North West); 9 = King Edward/Inkosi Albert Luthuli Central Hospital (referral 
for KwaZulu-Natal and parts of the Eastern Cape.)
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The parameters of the incidence trends 
were estimated using software for analysis 
of trends using Jointpoint Regression 
Program 3.5.4 of 2012 developed at the 
National Cancer Institute, Bethesda, USA. 
These analyses were based on the crude 
rate, assuming Poisson variance of counts. 
The joinpoints were identified using the 
Hudson method and their optimal num ber 
was determined by the permutation test.
Results
During the period 1987 - 2007, there were 
11 712 cancer cases reported to the registry. 
Thirteen of these were non-malignant 
tumours in sites other than the CNS and 
were excluded from the analyses. No second 
primary tumours were recorded. Overall, 
93.7% of cases were microscopically verified 
and in 0.7% of cases (n=77) the basis of 
the diagnosis was unknown. There were 
no cases identified from a death certificate 
only. The date of birth was imprecise in 
approximately 13% of all cases (day and 
month missing). There were 301 cases 
(2.6%) in which the patient was considered 
too young or too old for the given cancer 
type. One case of mixed carcinoma of major 
salivary gland in an infant was checked and 
confirmed. Less than 4% of cases (n=452) 
were classified into unspecified diagnostic 
categories. Of the tumours that occurred 
in the brain, 6.7% (n=90 cases) were non-
malignant. Information on laterality was 
available for 61.2% of retinoblastomas, 
56.9% of nephroblastomas and 64.3% of 
gonadal tumours.
Information on ethnicity was unavailable 
in 12 cases (0.1%). Of all cases, 67.9% 
occurred in black African, 15.0% in white, 
13.8% in coloured and 3.2% in Asian/Indian 
children. The overall male/female ratio was 
1.3, and varied by ethnic group (Table 3).
Based on the 11 699 cases included in 
the analyses, the overall ASR was 45.2 per 
million (Table 2). ASRs differed between 
the individual diagnostic groups and the 
ethnic groups (Table 3). The incidence 
rates were highest among white children 
in almost all diagnostic groups examined, 
except retinoblastoma and hepatic tumours 
(highest in coloured children), germ cell 
tumours (highest in Asian/Indian children) 
and Kaposi’s sarcoma (highest in black 
Africans).
The incidence rates differed between the 
provinces fivefold (data not shown); the 
highest ASRs per million were seen in the 
Western Cape (88.4) and Gauteng (81.0). 
The Western Cape was the province with the 
lowest proportion of black African (33%) 
and the largest proportion of coloured (49%) 
and white (16%) ethnicity. Gauteng also 
had a lower proportion of black African 
(77%) and a larger proportion of white 
(9%) populations compared with the other 
provinces. The lowest incidence rates were 
observed in the Eastern Cape (21.8) and 
Limpopo provinces (18.4). The overall ASRs 
were intermediate in the Northern Cape 
(52.9), Free State (64.3), KwaZulu-Natal 
(39.0), Mpumalanga (26.0) and North West 
(26.4) provinces.
A set of graphs (Fig. 2) shows the incidence 
trends for selected tumour groups. Over the 
21-year study period, the overall incidence 
rate (adjusted for age group and gender) was 
seen to decline by 1.2% per year for the whole 
country (p<0.01). However, the decline was 
not homogeneous during the study period. 
Overall rates decreased markedly between 
1987 and 1994 by 8.1% per year (p<0.001), 
and increased thereafter by 1.9% per year 
(p=0.002). Leukaemia dropped by 7.8% 
per year (p<0.001) to 1995 and increased 
by 1.7% per year (p=0.082) thereafter. The 
incidence of lymphomas decreased by 7% 
per year (p<0.004) until 1995 and then 
increased by 2.7% per year (p=0.03). The 
dramatic decline in the incidence of CNS 
tumours (–28.3; p=0.037) was reversed from 
1990, with a sustained increase of 4.7% per 
year (p<0.001).
Discussion
This is the first report of the SACTR, a 
member of the African Network of Cancer 
Registries (http://afcrn.org/) since its creation 
in January 2011. Compared with Globocan 
2012,[4] where the estimated incidence of all 
paediatric cancers (0 - 14 years) in Africa 
is 96 and 73 per million for boys and girls, 
respectively, the rates we observed are much 
lower. It should, however, be noted that the 
Globocan estimates are largely based on data 
from regional cancer registries, most of them 
urban, and they may therefore overestimate 
the national cancer incidence. The rural 
areas show lower rates.[11]
The observed overall ASR of 36.3 per 
million for black Africans is nevertheless 
low in comparison with the rates reported 
from Malawi (220 per million for males), 
Uganda (140 per million for females) or 
Zimbabwe[10] (Table 4). The lack of cases 
pertains predominantly to lymphomas, CNS 
tumours, retinoblastomas, bone tumours, 
carcinomas and possibly Kaposi’s sarcomas. 
Burkitt’s lymphoma is the most common 
childhood cancer in holoendemic malaria 
regions in Africa, with a strong association 
with both intense malaria infection and 
Table 1. Estimated average annual child population of SA in years 1987 - 2007, used 
for calculation of incidence rates
Age groups (years), n
  0 - 4 5 - 9 10 - 14 Total, N
Total 4 274 603 4 314 149 4 292 439 12 881 191
Gender
Boys 2 142 583 2 162 443 2 145 146 6 450 172
Girls 2 132 020 2 151 706 2 147 293 6 431 019
Ethnic group
Black 3 560 614 3 577 436 3 514 557 10 652 607
White 238 403 261 288 295 470 795 161
Coloured 370 882 368 748 370 591 1 110 221
Asian, Indian, Pakistani 77 068 82 929 90 287 250 284
Unknown 27 636 23 748 21 534 72 918
Province
Limpopo 571 368 607 058 595 942 1 774 368
North West 290 603 288 152 281 377 860 132
Mpumalanga 352 128 361 048 357 870 1 071 046
Gauteng 706 054 633 142 605 502 1 944 698
Free State 239 321 255 150 261 922 756 393
KwaZulu-Natal 945 778 953 332 963 744 2 862 854
Northern Cape 106 282 106 617 108 427 321 326
Western Cape 372 527 359 440 359 916 1 091 883
Eastern Cape 690 542 750 210 757 739 2 198 491
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Table 2. Numbers of cases and incidence rates by gender in the child population (0 - 14 years) for SA, 1987 - 2007
Diagnostic group n
Age-specific rate Crude 
rate ASR M/F
ASR
Cum. rate MV, % 0 - 4 5 - 9 10 - 14 Boys Girls
I Leukaemia 3 113 15.5 11.3 7.7 11.5 11.9 1.3 13.5 10.3 173 100.0
Ia Lymphoid leukaemias 2 081 11.1 7.7 4.4 7.7 8.0 1.4 9.4 6.7 115 100.0
Ib Acute myeloid 
leukaemias
862 3.8 3.1 2.7 3.2 3.2 1.2 3.5 3.0 48 100.0
Ic Chronic 
myeloproliferative 
diseases
119 0.4 0.4 0.5 0.4 0.4 1.0 0.4 0.4 7 100.0
Id MDS and other 
diseases
18 0.2 0.0 0.0 0.1 0.1 1.6 0.1 0.1 1 100.0
Ie Unspecified 
leukaemias
33 0.2 0.2 0.0 0.1 0.1 2.0 0.2 0.1 2 100,0
II Lymphomas and 
related neoplasms
1 595 4.9 7.4 5.4 5.9 5.8 2.2 8.0 3.6 88 99.9
IIa Hodgkin’s 
lymphomas
612 1.0 3.2 2.6 2.3 2.2 2.9 3.2 1.1 34 99.8
IIb Non-Hodgkin’s 
lymphomas (except 
Burkitt’s lymphoma)
563 1.6 2.5 2.1 2.1 2.0 1.7 2.6 1.5 31 99.8
IIc Burkitt’s lymphoma 378 2.0 1.6 0.6 1.4 1.5 2.4 2.1 0.9 21 100.0
IId Miscellaneous 
lymphoreticular 
neoplasms
29 0.3 0.0 0.0 0.1 0.1 0.9 0.1 0.1 2 100.0
IIe Unspecified 
lymphomas
13 0.0 0.1 0.0 0.0 0.0 3.3 0.1 0.0 1 100.0
III CNS neoplasms 1 334 5.9 6.0 3.0 4.9 5.1 1.1 5.4 4.8 74 73.8
IIIa Ependymomas 
and choroid plexus 
tumours
110 0.7 0.4 0.2 0.4 0.4 1.2 0.5 0.4 6 100.0
IIIb Astrocytomas 352 1.5 1.6 0.9 1.3 1.3 1.1 1.4 1.3 20 99.1
IIIc CNS embryonal 
tumours
323 1.7 1.1 0.7 1.2 1.2 1.4 1.4 1.1 18 100.0
IIId Other gliomas 272 1.1 1.5 0.4 1.0 1.0 0.9 1.0 1.1 15 51.8
IIIe Other specified CNS 
neoplasms
62 0.1 0.3 0.3 0.2 0.2 0.8 0.2 0.3 3 98.4
IIIf Unspecified CNS 
neoplasms
215 0.8 1.0 0.5 0.8 0.8 1.3 0.9 0.7 12 0.0
IV Neuroblastoma 748 6.3 1.3 0.6 2.8 3.1 1.3 3.4 2.7 42 94.3
IVa Neuroblastoma and 
ganglioneuroblastoma
740 6.3 1.3 0.6 2.7 3.0 1.3 3.4 2.7 41 94.2
IVb Other peripheral 
nervous cell tumours
8 - 0.0 0.1 0.0 0.0 1.7 0.0 0.0 0 100.0
V Retinoblastoma 779 7.8 0.8 0.1 2.9 3.3 1.2 3.5 3.1 43 84.5
VI Renal tumours 1 568 12.6 3.9 1.0 5.8 6.4 1.0 6.5 6.3 87 96.0
VIa Nephroblastoma and 
other tumours
1 557 12.5 3.8 0.9 5.8 6.4 1.0 6.4 6.3 87 96.0
VIb Renal carcinomas 11 0.0 0.1 0.0 0.0 0.0 0.6 0.0 0.0 1 100.0
VIc Unspecified 
malignant renal 
tumours
0 - - - - -  - - - - -
VII Hepatic tumours 240 1.6 0.4 0.6 0.9 0.9 1.5 1.1 0.8 13 92.9
VIIa Hepatoblastoma 152 1.5 0.1 0.1 0.6 0.6 1.5 0.8 0.5 8 100.0
VIIb Hepatic carcinomas 75 0.1 0.3 0.5 0.3 0.3 1.5 0.3 0.2 4 93.3
Continued ...
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Table 2. (continued) Numbers of cases and incidence rates by gender in the child population (0 - 14 years) for SA, 1987 - 2007
Age-specific rate Crude 
rate ASR M/F
ASR
Cum. rate MV, %Diagnostic group n 0 - 4 5 - 9 10 - 14 Boys Girls
VIIc Unspecified malignant 
hepatic tumours
13 0.0 0.1 0.0 0.0 0.0 0.9 0.0 0.1 1 7.7
VIII Malignant bone 
tumours
473 0.5 1.5 3.2 1.7 1.6 1.1 1.7 1.6 26 99.2
VIIIa Osteosarcomas 359 0.3 1.1 2.7 1.3 1.2 1.0 1.2 1.2 20 100.0
VIIIb Chondrosarcomas 3 - - 0.0 0.0 0.0 0.0 - 0.0 0 100.0
VIIIc Ewing tumour and 
sarcomas of bone
100 0.3 0.4 0.4 0.4 0.4 1.2 0.4 0.3 6 100.0
VIIId Other specified bone 
tumours
3 0.0 0.0 - 0.0 0.0 2.0 0.0 0.0 0 100.0
VIIIe Unspecified 
malignant bone 
tumours
8 - 0.0 0.1 0.0 0.0 1.7 0.0 0.0 0 50.0
IX Soft-tissue sarcomas 1 087 5.7 3.7 2.7 4.0 4.2 1.5 4.9 3.4 60 96.7
IXa Rhabdomyosarcomas 711 4.1 2.3 1.4 2.6 2.8 1.4 3.2 2.4 39 100.0
IXb Fibrosarcomas 70 0.4 0.1 0.2 0.3 0.3 1.3 0.3 0.2 4 100.0
IXc Kaposi’s sarcoma 147 0.6 0.8 0.2 0.5 0.6 2.1 0.8 0.4 8 76.2
IXd Other specified soft-
tissue sarcomas
102 0.3 0.3 0.5 0.4 0.4 1.2 0.4 0.3 6 100.0
IXe Unspecified soft-
tissue sarcomas
57 0.2 0.2 0.2 0.2 0.2 1.7 0.3 0.2 3 98.2
X Germ cell tumours 436 2.8 1.0 1.1 1.6 1.7 0.5 1.1 2.3 24 99.1
Xa CNS germ cell 
tumours
13 0.0 0.0 0.1 0.0 0.0 1.6 0.1 0.0 1 100.0
Xb Other extragonadal 
germ cell tumours
297 2.3 0.6 0.5 1.1 1.2 0.4 0.7 1.7 17 100.0
Xc Malignant gonadal 
germ cell tumours
111 0.4 0.4 0.4 0.4 0.4 0.5 0.3 0.5 6 99.1
Xd Gonadal carcinomas 4 0.0 - 0.0 0.0 0.0 1.0 0.0 0.0 0 100.0
Xe Other, unspecified 
gonadal tumours
11 0.1 - 0.1 0.0 0.0 0.1 0.0 0.1 1 72.7
XI Carcinomas and 
melanomas
223 0.6 0.6 1.3 0.8 0.8 1.0 0.8 0.8 12 97.3
XIa Adrenocortical 
carcinomas
18 0.2 0.0 0.0 0.1 0.1 0.8 0.1 0.1 1 94.4
XIb Thyroid carcinomas 20 0.0 0.1 0.1 0.1 0.1 0.8 0.1 0.1 1 100.0
XIc Nasopharyngeal 
carcinomas
51 0.0 0.1 0.4 0.2 0.2 1.3 0.2 0.2 3 100.0
XId Malignant 
melanomas
29 0.1 0.1 0.1 0.1 0.1 0.6 0.1 0.1 2 86.2
XIe Skin carcinomas 27 0.1 0.1 0.1 0.1 0.1 2.0 0.1 0.1 1 96.3
XIf Other and 
unspecified 
carcinomas
78 0.1 0.2 0.5 0.3 0.3 0.9 0.3 0.3 4 100.0
XII Other and 
unspecified 
neoplasms
103 0.6 0.3 0.2 0.4 0.4 0.9 0.4 0.4 6 12.6
XIIa Other specified 
malignant tumours
12 0.1 0.0 0.0 0.0 0.0 0.5 0.0 0.1 1 100.0
XIIb Other unspecified 
malignant tumours
91 0.5 0.3 0.2 0.3 0.4 1.0 0.4 0.3 5 1.1
Total 11 699 64.8 38.1 26.9 43.2 45.2 1.3 50.4 40.0 649 93.7
ASR = age-standardised rate (all rates are expressed per million); M/F = male/female ratio; Cum. rate = cumulative rate; MV = microscopic verification. 
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Epstein-Barr virus.[12,13] In SA, malaria is present only in very small 
areas and Burkitt’s lymphoma is sporadic. In sub-Saharan Africa, 
with a high prevalence of HIV, the incidence of Kaposi’s sarcoma 
in children has increased considerably over the past 30 years. 
However, even if the prevalence of HIV in SA (17.9%)[14] is higher 
than in Uganda (7.2%)[10] or Zambia (12.7%),[15] the incidence rates 
of Kaposi’s sarcoma in SA are much lower than in other southern 
African countries.[11] This may be explained by the comparatively 
low rates of endemic Kaposi’s sarcoma in SA[16] and the lower 
prevalence of human herpesvirus infection in SA than, for example, 
in Uganda.[17]
The overall incidence rates for the white population (ASR 116.2 
per million) are rather low, but comparable with rates observed in 
the 1980s in some populations of South America (ASR 118 - 136 
Table 3. Cancer incidence in the childhood population (age 0 - 14 years) for SA, 1987 - 2007, according to ethnic group
Ethnic group
Diagnostic group
Black White Coloured Asian
n ASR M/F n ASR M/F n ASR M/F n ASR M/F
I 1 820 8.2 1.4 643 43.4 1.2 493 22.1 1.2 153 33.1 1.6
Ia 1 072 4.9 1.5 520 35.3 1.2 357 16.1 1.4 128 27.8 1.5
Ib 623 2.8 1.3 98 6.5 0.9 117 5.1 0.8 24 5.0 2.4
II 1 095 4.9 2.3 231 13.5 2.0 225 9.5 2.5 43 8.3 1.5
IIa 426 1.8 3.5 74 4.1 1.7 91 3.7 2.6 21 3.9 1.3
IIb, d, e 240 1.1 2.3 59 3.6 2.5 71 3.2 2.9 7 1.5 2.5
IIc 429 1.9 1.6 98 5.8 1.9 63 2.6 2.0 15 2.9 1.5
III 786 3.6 1.1 251 16.1 1.4 266 11.6 1.2 31 6.2 0.6
IIIa 63 0.3 1.1 25 1.7 1.5 20 0.9 1.5 2 0.5 0.0
IIIb 182 0.8 1.0 79 5.0 1.3 82 3.5 1.2 9 1.9 0.8
IIIc 170 0.8 1.5 73 4.7 1.7 72 3.2 0.9 8 1.5 0.3
IIId 178 0.8 0.8 44 2.9 1.3 44 1.9 1.3 6 1.2 0.5
IIIe 43 0.2 0.7 8 0.5 0.6 8 0.3 1.7 3 0.5 0.5
IIIf 150 0.7 1.3 22 1.4 1.4 40 1.7 1.4 3 0.6 2.0
IVa 444 2.2 1.3 156 11.3 1.3 112 5.4 1.3 26 5.9 1.2
V 664 3.4 1.2 37 2.8 1.1 67 3.3 0.7 11 2.6 1.2
VIa 1 256 6.2 1.1 126 9.2 0.7 143 6.8 0.9 30 6.8 1.1
VII 160 0.7 1.6 25 1.7 1.1 49 2.3 1.4 5 1.2 1.5
VIIa 90 0.4 1.4 16 1.2 2.2 40 2.0 1.9 5 1.2 1.5
VIIb 60 0.2 2.0 6 0.3 0.5 9 0.4 0.5 0 - -
VIII 310 1.3 1.1 88 4.8 1.1 57 2.2 0.8 17 2.9 0.9
VIIIa 260 1.1 1.1 47 2.5 1.1 44 1.7 0.8 8 1.3 0.3
VIIIc 39 0.2 1.4 41 2.3 1.1 11 0.4 0.8 8 1.4 1.7
IX 861 4.0 1.4 98 6.5 1.5 97 4.3 1.3 30 6.6 3.3
IXa 560 2.6 1.3 66 4.4 1.8 60 2.7 1.4 24 5.4 3.0
IXb 52 0.2 1.4 10 0.7 0.7 8 0.4 3.0 0 - -
IXc 140 0.6 2.2 1 0.1 - 5 0.2 0.7 1 0.2 -
IXd 68 0.3 1.1 15 0.8 1.5 14 0.6 0.8 5 1.0 4.0
IXe 41 0.2 2.2 6 0.4 1.0 10 0.4 1.0 0 - -
X 298 1.4 0.4 56 3.6 0.8 59 2.7 0.4 23 5.1 1.9
Xb 219 1.1 0.4 28 1.9 0.5 37 1.8 0.3 13 3.0 1.6
Xc 69 0.3 0.4 18 1.2 1.0 16 0.7 0.3 8 1.7 3.0
XI 152 0.6 1.1 40 2.2 0.6 27 1.1 1.5 4 0.8 0.3
XIc 38 0.2 1.9 5 0.3 0.3 8 0.3 0.6 0 - -
XIf 62 0.3 0.9 7 0.4 0.4 7 0.3 6.0 2 0.4 0.0
XII 84 0.4 1.1 6 0.4 0.2 13 0.6 0.6 0 - -
Total 7 942 36.9 1.3 1 758 115.8 1.2 1 614 72.2 1.2 373 79.5 1.4
ASR = age-standardised rate per million; M/F = male/female ratio.
RESEARCH
945       November 2015, Vol. 105, No. 11
per million) and Eastern Europe (ASR ~125 per million).[10] The 
higher incidence rates in the white compared with the black African 
population may be explained by a better rate of diagnosis and access 
to tertiary healthcare treatment in a POU. The cultural background 
and genetic factors may also be relevant, as the higher incidence rates 
in the white population, compared with the black, are also observed 
in the USA.[10] Our rates for the Asian/Indian ethnic group (ASR 79 
per million) are at the lower end of the ASR range observed in India 
and the developing countries of South-East Asia in the 1980s or early 
1990s (74 - 110 per million).[10] As black African children constitute 
two-thirds of the total dataset, their very low registration rates impact 
heavily on the national incidence estimates.
The low incidence rates may be partly explained by under-
diagnosing, misdiagnosing or under-reporting. The diagnosis of 
many tumours, in particular those of the CNS, may be delayed as 
the appropriate technology required to confirm the diagnosis is not 
always available.[18] In many rural areas there is also cultural pressure 
that traditional healers should be consulted before modern medical 
services are accessed. All these obstacles lead to children dying 
without a proper diagnosis, referral and treatment. For the majority 
of SA citizens, the public health system is the only means to access the 
POUs. Once the diagnosis has been suspected or confirmed, patients 
are likely to be referred to and registered by a POU.
It is possible that some cases are diagnosed but not registered. The 
lack of medical services in some provinces impacts on both access to 
care and the likelihood of being diagnosed and registered. Although 
under-registration should not differ between the ethnic groups, 
reporting may be more difficult in more deprived areas where the 
proportion of black African population is larger. Limpopo and the 
Eastern Cape have the highest proportion of population (55%) with 
no income, while in the two provinces with the highest incidence 
rates, Gauteng and Western Cape, this proportion is lower (41%).[1] 
Table 4 shows the impact of exclusion of the provinces with lowest 
rates.
There are a number of smaller centres and individual practices 
that are able to diagnose and treat children with cancer but do 
not necessarily send data to the SACTR. Although the SACCSG 
encourages reporting to the SACTR, the registration process remains 
challenging. As a consequence, the rates reported here should be 
considered minimal estimates of the true status.
Deaths are certified in SA, and there is a central collection of 
death certificates. The SACTR did not attempt to link these records 
with the registry database, as the quality of their information has 
been assessed as low.[19] In countries where death data are available 
to cancer registries, these may help to achieve higher registration 
completeness, provided the causes of death are correctly assessed 
and coded.
The correct incidence estimates depend on the registration quality 
as much as on the population data. We had to estimate figures for a 
large number of categories under many assumptions, which may have 
influenced the incidence rates in some ethnic groups and provinces 
more than others. There could also have been a mismatch of the 
classification of ethnic group or province between the official data 
and the SACTR, which would have affected the calculated rates in 
subgroups.
Internationally, ASRs for childhood cancers have tended to increase 
in recent decades, while our data show a decrease in incidence rates 
over the study period. The overall decline was caused by the high 
rates observed at the beginning of the period. In particular, the 
dramatic decline in the rates of the CNS tumours in whites between 
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Fig. 2. Time trends of childhood cancer incidence (age 0 - 14 years) in SA.
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1987 and 1989 may suggest a break in links between the registry 
and the neurosurgical departments. This pattern could also reflect 
inclusion of prevalent cases in the first years of registration, typical 
of new cancer registries. The annual rates stabilised for several 
tumour types from 1995, and further close monitoring of the trends 
is required.
National cancer registration for all ages was launched in SA 
in 1986 under the auspices of the National Health Laboratory 
Service. However, this initially relied on voluntary reporting, which 
mostly came from pathological laboratories and isolated physicians. 
Clinically diagnosed cases (6% in the present series) were therefore 
not registered. The National Cancer Registry (NCR) was revitalised 
on the initiative of the Department of Health on 26 April 2011 with 
Government Notice No. R.380, stipulating compulsory reporting of 
all cancers to the NCR based in Johannesburg.
Since 2011, POUs have submitted the same dataset to both the 
NCR and the SACTR every 3 months. The databases of both cancer 
registries should therefore be equally complete and include the same 
registered tumours. However, from a recently published report[20] 
based on data from the NCR for 2000 - 2006 it became evident that 
further efforts are required to unify the registration procedures and 
strengthen collaboration between the two cancer registries. Although 
the overall rate they reported (45.7 per million) was very similar to 
ours (45.2/million), there are differences in the incidence rates of 
several diagnostic groups. These differences may be caused by the 
use of additional data sources by the NCR, which would explain 
the higher incidence rates of lymphomas, epithelial neoplasms, 
soft-tissue sarcomas and bone tumours. The SACTR may be more 
efficient in excluding unconfirmed diagnoses, metastatic extension of 
primary tumours, duplicate registrations of such tumours, etc. On the 
other hand, the SACTR reports higher incidence rates of leukaemia 
and solid tumours characteristic of the paediatric age range, such as 
retinoblastoma, neuroblastoma or renal tumours.
The continued work of the SACTR is required for multiple 
reasons. First, the data on childhood cancers are collected through 
the network of the POUs that ensures a link to detailed clinical 
Table 4. Comparison of the reported age-standardised (world) incidence rates in selected populations in Africa
Country Mali Namibia Nigeria Uganda Zimbabwe SA SA SA
Region Bamako National Ibadan Kampala Harare, black 
Africans
SACTR Selected 
regions*
Black 
Africans
Reporting period 1987 - 1995 1983 - 1992 1985 - 1992 1992 - 1995 1990 - 1994 1987 - 2007 1987 - 2007 1987 - 2007
Source IICC-2 IICC-2 IICC-2 IICC-2 IICC-2 Current 
data
Current 
data
Current 
data
Cases, N 226 241 383 340 219 11 699 9 640 7 942
Diagnostic group, ASR
I Leukaemia 3.1 6.2 8.3 10.6 23.1 11.9 15.2 8.2
Ia  Lymphoid  
leukaemia
0.7 4.5 2.6 3.3 11.6 8.0 10.4 4.9
II Lymphomas 17.2 5.8 27.1 52.9 12.5 5.8 7.9 4.9
IIa  Hodgkin’s  
lymphoma
6.6 2.0 3.3 2.2 3.5 2.2 3.0 1.8
IIc  Burkitt’s  
lymphoma
1.7 1.9 18.0 36.1 2.4 1.5 2.0 1.9
III CNS tumours 1.4 7.3 11.1 2.3 12.0 5.1 7.2 3.6
IV Symp. nervous 
system tumours
0.0 3.6 0.2 1.0 4.0 3.1 4.1 2.2
V Retinoblastoma 24.5 4.5 7.4 11.1 10.5 3.3 4.0 3.4
VI Renal tumours 12.2 6.4 4.9 8.0 16.5 6.4 8.0 6.2
VIa Nephroblastoma 4.8 6.0 4.7 8.0 16.5 6.4 7.9 6.2
VII Hepatic tumours 3.7 0.2 1.1 2.7 2.1 0.9 1.2 0.7
VIII Bone tumours 2.7 3.4 2.1 5.6 4.3 1.6 2.2 1.3
IX Soft-tissue sarcomas 2.7 4.6 5.4 73.4 19.7 4.2 5.5 4.0
IXc Kaposi’s sarcoma 0.0 0.7 0.0 67.5 10.6 0.6 0.8 0.6
X Germ cell and 
gonadal tumours 
2.7 1.1 0.4 1.7 2.5 1.7 2.4 1.4
XI Epithelial and 
melanoma
5.5 2.4 1.7 7.3 2.7 0.8 1.1 0.6
XII Other and un specified 
neoplasms 
2.0 0.4 0.8 6.2 1.6 0.4 0.6 0.4
Total 77.7 45.9 70.5 182.7 111.6 45.2 59.3 36.9
IICC-2 = International Incidence of Childhood Cancer, vol. 2;[10] ASR = age-standardised rate per million.
*Excluding Limpopo, Eastern Cape and North West.
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information on each patient, which is not mandated by the NCR. 
Supporting the SACTR enables the SACCSG to have the feedback 
required for deciding on new treatment protocols, improving data 
quality and describing outcome results in terms of survival. The 
POUs also strive to acquire data on some patients from private 
practice through the paediatrician links, which would not necessarily 
be possible through the general cancer registry with an at least 
20-fold higher volume of cases. Specific focus on childhood cancer 
helps to improve registration in this age range. The NCR continues 
to present itself as a pathology cancer registry,[21] and no report on 
cancer incidence for all ages has been produced to date. It is likely 
that only the childhood cancer data are of sufficient quality, to a large 
extent attributable to the work of the SACTR and SACCSG.
Conclusions
The SACTR is the first paediatric population-based cancer 
registry established in Africa, and it has national coverage. Despite 
uncertainties inherent in the presented data, the SACTR constitutes 
an invaluable resource of information for policy planning and 
research. This report challenges us to improve the diagnosis and 
notification of childhood cancer to both the NCR and the SACTR, 
and to tackle the ethnic inequalities in access to appropriate care. 
Continuous collection of data is indispensable for evaluation of 
demographic, geographical and temporal variations. Ultimately this 
will lead to earlier diagnosis, better management, and improved 
outcomes for children with cancer in SA.
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